Skip to main content
. 2016 May 9;7(24):36971–36987. doi: 10.18632/oncotarget.9235

Figure 7. MAPK pathway increases cleaved-Par-4 protein.

Figure 7

A-C. Cl-Par-4 cancer cells were treated with either 10μM MAPK inhibitor (U0126) or 50μM MAPK inhibitor (PD98059) for 24h. The levels of p-ERK 1/2 (Thr202/Tyr204), p-AKT (Ser473), AKT and cl-Par-4-myc were determined in treated cells using western blot analysis. GAPDH was used as a loading control. Results shown are representative of three independent experiments.